Business News • PR NewsWire • EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

EYLEA® (aflibercept) Injection Submitted for EU Marketing Authorization for the Treatment of Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

TARRYTOWN, N.Y., June 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for...

View More : http://www.prnewswire.com/news-releases/eylea-aflibercept-injection-submitted-for-eu-marketing-authorization-for-the-tre...

Releted News by prnewswire

Cybercrime : des vérifications en ligne aident à retrouver des données personnelles volées

Herman Miller erweckt Living Office(SM) zum Leben

Industrial Services Market: A New Business Frontier for Profitability